Skip to main content

  • Clinical Outcome of Transcatheter Aortic Valve Replacement With TriGUARD 3™ Cerebral Embolic Protection Device

    • Posted: 05/01/2023
    • Author:

      Sayonara M. Daal, Gian M.J. Jimenez-Rodriguez, Michiel Voskuil, Adriaan O. Kraaijeveld, Thomas C. Dessing, Faiz Z. Ramjankhan, Mostafa M. Mokhles and Pieter R. Stella

    • 2023CRM

    Abstract

    Objective

    Periprocedural stroke during transcatheter aortic valve replacement (TAVR) is a highly feared adverse event. The TriGUARD 3 cerebral embolic protection device (CEPD) may have the potential benefit of reduction of embolic events, but it still remains unclear whether it reduces the incidence of periprocedural stroke or transient ischemic attack (TIA).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details